MONITORING TECHNIQUES FOR OPTIMAL DIABETES MANAGEMENT AND CONTROL Final Examination Questions Select the best answer for each question and complete your test online at EliteLearning.com/Book 86. How frequently should a patient with type 1 diabetes on an intense insulin regimen monitor blood glucose levels? a. While fasting and 1 to 2 hours after meals. b. Twice daily at varying times. c. Before meals and snacks, before bedtime, and occasion- ally postprandially. d. At variable intervals depending on treatment program and patient characteristics
91. Which of the following is a barrier to successful use of a CGM? a. A1C within an acceptable glycemic range. b. Use of regular insulin. c. Cost of CGM. d. Poor venous access. 92. The hemoglobin A1C measures: a. Mean glucose over the preceding 6 weeks. b. Weighted mean glucose from the preceding 12 weeks. c. Random glucose levels. d. Frequency of hypoglycemia. 93. Most continuous glucose monitoring (CGM) systems allow wireless sensors to stay in place for: a. 1 to 3 days. b. 3 to 7 days. c. 7 to 14 days. d. 21 days. 94. CGM measures glucose levels in which of the following? a. Interstitial fluid. b. Venous fluid. c. Transcellular fluid. d. Vascular fluid. 95. Time in range (TIR) is a useful glucose metric referring to: a. The percentage of time a person’s blood glucose levels change throughout the day. b. The percentage of time a person’s blood glucose levels capture high values. c. The percentage of time a person’s blood glucose levels capture low value. d. The percentage of time a person’s blood glucose level remains in a proposed target range.
87. John is a 35-year-old male whose postprandial capillary blood glucose level was 165 mg/dL 2 hours after dinner. What conclusions can be drawn from these results? a. The blood glucose level is within recommendations for ADA glucose targets. b. The blood glucose level is higher than recommended for ADA glucose targets. c. The blood glucose level is lower than recommended for ADA glucose targets. d. The blood glucose level is higher than recommended for ADA targets in males. 88. What is the function of A1Cs? a. Provide information on glycemic variability or hypogly- cemia. b. Strong predictive value for diabetes complication. c. Indirect measure of glycemia over the preceding 30 days. d. Direct measure of a random fasting glucose 89. Benefits of continuous glucose monitoring (CGM) include:
a. Wearing 2 to 3 days, depending on the device. b. Recording glucose levels every 15 to 20 minutes. c. Equally effective as BGM. d. Providing fast, proactive response.
90. What continuous glucose monitoring (CGM) device collects blood glucose data and transmits it to a health care provider in a blinded mode? a. Personal. b. Professional. c. Open-loop d. Closed-loop.
Course Code: RPTX02DC
Page 119
Book Code: RPTX3024
EliteLearning.com/Pharmacy
Powered by FlippingBook